NUDT15 and autoimmune hepatitis: Safety and efficacy can be maintained in most NUDT15 heterozygous genotype patients on AZA at lower doses of approximately 1 mg ⋅ kg−1 ⋅ d−1, which is the basic therapeutic dosage for AIH.